Lupus patients get new hope from Ultra-Fast CAR-T therapy trial
NCT ID NCT07331467
First seen Jan 12, 2026 · Last updated Jun 22, 2026 · Updated 28 times
Summary
This early-stage trial tests a new type of CAR-T cell therapy, made quickly from a patient's own immune cells, for people with severe lupus that hasn't improved with standard treatments. The study will enroll 18 adults to check if the therapy is safe and can reduce disease activity. Researchers will monitor side effects and measure changes in lupus symptoms over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Drum Tower Hospital, Medical School of Nanjing University
RECRUITINGNanjing, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CD19-targeted CAR-T cells
What this could lead to
If successful, this could offer a new treatment option for people with severe lupus that hasn't responded to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 18 participants, so results may not apply widely. CAR-T therapy carries risks like severe immune reactions and infections.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.